Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) announced the FDA raised no objections to advancing pilavapadin into Phase 3 development for treating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE